Silo Pharma Says EPO Grants Patent Covering Preventative Approach Of Lead Candidate SPC-15, Intranasal, Nose-To-Brain Treatment Targeting PTSD And Stress-Induced Affective Disorders
Patent strengthens global IP protection for novel treatment approach designed to prevent stress-induced psychiatric disorders before symptoms developSARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma
Silo Pharma got official permission (a patent) to be the only company that can make their special nose medicine for PTSD. This is like getting a lock on their invention, which shows their idea passed tough tests and might be valuable.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.